Q&A: Will Moderna’s mRNA RSV vaccine increase uptake next respiratory virus season?

In late May, the FDA announced approval of Moderna's mResvia, a messenger RNA vaccine to protect adults 60 years or older from lower respiratory tract disease caused by respiratory syncytial virus.
This marked the third vaccine approved for respiratory syncytial virus but the first time mRNA technology was used for preventing a disease other than COVID-19. The company said at the time of the approval that it expects to have mResvia available for eligible populations in the U.S. within the next year.
With three RSV vaccines now available and low uptake reported during the last RSV season —

In late May, the FDA announced approval of Moderna’s mResvia, a messenger RNA vaccine to protect adults 60 years or older from lower respiratory tract disease caused by respiratory syncytial virus.
This marked the third vaccine approved for respiratory syncytial virus but the first time mRNA technology was used for preventing a disease other than COVID-19. The company said at the time of the approval that it expects to have mResvia available for eligible populations in the U.S. within the next year.
With three RSV vaccines now available and low uptake reported during the last RSV season —